Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s
Vertex's new medicine worked much better than a fake pill in kidney disease tests. The FDA will decide by late November if patients can use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.